Unbiased News Awaits.
Get Started
SubscribeLogin
Eurovision
Social Media
Baseball
Pope Francis
Israel-Hamas Conflict
Hamas
Boxing
Natural Disasters
Artificial Intelligence
Premier League
Vladimir Putin
European Union
Published • loading... • Updated

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC

Summary by onclive.com
The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

4 Articles

All
Left
Center
Right
Pharmacy TimesPharmacy Times

Sacituzumab Govitecan-hziy Plus Pembrolizumab Improves PFS in Patients With Metastatic Triple-Negative Breast Cancer

The combination yielded superior progression-free (PFS) survival compared with standard of care.

Read Full Article
onclive.comonclive.com

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC

The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.

Read Full Article
cancernetwork.comcancernetwork.com

Sacituzumab Govitecan/Pembrolizumab Yields Significant PFS Improvement in TNBC

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Read Full Article
targetedonc.comtargetedonc.com

Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1+ TNBC

ASCENT-04 data showed sacituzumab govitecan plus pembrolizumab improved progression-free survival in PD-L1+ metastatic triple-negative breast cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

targetedonc.com broke the news in on Monday, April 21, 2025.
Sources are mostly out of (0)

Similar News Topics

Gilead Sciences

Gilead Sciences

News
For You
SearchBlindspotLocal